GO
Loading...

Pharmacyclics Inc

More

  • Feb 12- U.S. health regulators on Wednesday approved the Johnson& Johnson and Pharmacyclics Inc cancer drug Imbruvica to treat chronic lymphocytic leukemia, a slowly progressing form of blood cancer.

  • J&J, Pharmacyclics drug gets U.S. approval for leukemia Wednesday, 12 Feb 2014 | 1:19 PM ET

    Feb 12- U.S. health regulators on Wednesday approved the Johnson& Johnson and Pharmacyclics Inc cancer drug Imbruvica to treat chronic lymphocytic leukemia, a slowly progressing form of blood cancer. The Food and Drug Administration decision marks the second approval recently for the medicine, known chemically as ibrutinib.

  • Jan 7- Pharmacyclics Inc said its cancer drug, Imbruvica, met its main goal of increasing patients' survival without their cancer worsening in a late-stage trial testing it for a rare blood disorder called chronic lymphocytic leukemia.

  • Jan 7- Pharmacyclics Inc said its cancer drug, Imbruvica, met its main goal of increasing patients' survival without their cancer worsening in a late-stage trial. The company's stock rose 5 percent at $110.60 on Tuesday on the Nasdaq after the company said an independent safety committee recommended an early halt of the trial.

  • Dec 8- A closely watched leukemia drug developed by Johnson& Johnson and Pharmacyclics Inc maintained its effectiveness in keeping the disease at bay for most patients, according to long-term follow-up data from a midstage study being presented at a major medical meeting.

  • Nov 13- U.S. health regulators on Wednesday approved a drug to treat a rare and aggressive form of non-Hodgkin lymphoma developed by Johnson& Johnson and Pharmacyclics Inc, becoming the second drug that had received the FDA's new breakthrough therapy designation to gain approval.

  • Nov 13- U.S. health regulators on Wednesday approved a drug to treat a rare and aggressive form of non-Hodgkin lymphoma developed by Johnson& Johnson and Pharmacyclics Inc, marking the second drug that received the FDA's new breakthrough therapy designation to gain approval.

  • Lightning Round: Apple, Arena Pharma & More Monday, 11 Nov 2013 | 6:42 PM ET

    It’s time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Lightning round: Wolverine World Wide and more Monday, 4 Nov 2013 | 6:59 PM ET

    "Mad Money" host Jim Cramer made calls on stocks viewers asked about.

  • Cramer: Biggest blockbuster drug in ages? Friday, 27 Sep 2013 | 6:24 PM ET

    Cramer wants you to know about the company behind this potential breakthrough cancer drug.

  • Cramer: Easy Money Over, Ring the Register Monday, 1 Jul 2013 | 6:25 PM ET

    The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.

  • TheStreet.com details the 10 best-performing biopharmaceutical stocks of 2012 and their outlook for 2013.

  • No Magic in Anti-Obesity Pills and Profits Monday, 16 Jul 2012 | 6:17 PM ET

    Jim Cramer’s researcher, Nicole Urken, reiterates the importance of assessing risk when speculating.

  • Your All-Star in Cramer's #StockDerby Tuesday, 10 Jul 2012 | 6:46 PM ET

    Find out which second-quarter top performer got the most votes.

  • Vote for Your All-Star in Cramer's #StockDerby Monday, 9 Jul 2012 | 9:14 PM ET
    Jim Cramer

    Tell Cramer which second-quarter top performer is your All-Star!

  • Major Wave of Biotech Mergers Expected Thursday, 26 Jan 2012 | 2:48 PM ET

    Amgen and Celgene, looking to boost oncology offerings, announced separate deals for small biotech companies Thursday, the latest in what analysts expect to be a major wave of biotech mergers.

  • Turning Up the Heat (Again) on the FDA Tuesday, 14 Aug 2007 | 3:08 PM ET
    FDA

    For the second time in two weeks, an op-ed item appears in The Wall Street Journal today calling out the FDA for its record on timely approval of cancer drugs.

  • This morning we learned that the FDA has issued another "approvable" letter to Pozen and GlaxoSmithKline for their migraine drug Trexima over safety concerns. POZN shares are down big. The company has scheduled a conference call for 11 a.m. ET. This is the third regulatory stumbling block for this drug and puts it on a timeline now where it could end up competing...

Most Popular Video

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.

Thursday, 17 Apr 2014 | 11:00 AM ET

Phil LeBeau has the details on the latest rides at this year's New York Auto Show.

Monday, 14 Apr 2014 | 11:43 AM ET

Dr. Steven Horng, Beth Israel Deaconess Medical Center, explains how Google Glass provided crucial support in an emergency situation and helped save a life.